Nuria Diaz Buezo

This inventor holds 10 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 4 EPO patents. Top assignee: Eli Lilly and Company. Active years: 2007-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nuria Diaz Buezo. Retrieved from https://idiyas.com/inventor/nuria-diaz-buezo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 3)

% Patents Active = 60.0

CIPO Patents = 4

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 69(Granted Patents)

Location History:

Alcobendas Madrid, ES (2008)
Madrid, ES (2007 - 2022)

Company Filing History:

10 out of 4,514

Eli Lilly and Company

patents

Years Active: 2007-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12454511 - 6-methoxy-3,4-dihydro-1H-isoquinolin compounds (2025-10-28),

2. 12441714 - Pyrrolidine compounds (2025-10-14),

3. 11286249 - Pyrrolidine compounds (2022-03-29),

4. 9416138 - Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors (2016-08-16),

5. 8232289 - Spiropiperidine compounds as ORL-1 receptor antagonists (2012-07-31),

6. 8173695 - Kappa selective opioid receptor antagonist (2012-05-08),

7. 7709522 - Kappa selective opioid receptor antagonist (2010-05-04),

8. 7414132 - Opioid receptor antagonists (2008-08-19),

9. 7381719 - Diaryl ethers as opioid receptor antagonist (2008-06-03),

10. 7288543 - Opioid receptor antagonists (2007-10-30),

Title: Nuria Diaz Buezo: Innovator in Pharmaceutical Compounds

Introduction

Nuria Diaz Buezo is a notable inventor based in Madrid, Spain. With six patents to her name, she has made significant contributions to the field of pharmaceuticals. Her work primarily focuses on developing innovative compounds that target various medical conditions, showcasing her expertise and commitment to advancing therapeutic solutions.

Latest Patents

Among her latest patents, Nuria has developed benzyl sulfonamide compounds that serve as MoGAT-2 inhibitors. This invention provides compounds of Formula I, wherein R1, L, and A are defined in her research. These compounds have potential applications in treating conditions such as hypertriglyceridemia. Additionally, she has introduced spiropiperidine compounds that act as ORL-1 receptor antagonists. This patent outlines the formula, its uses, and the methods for its preparation, indicating her focus on expanding the arsenal of therapeutic agents available for clinical use.

Career Highlights

Nuria Diaz Buezo currently works at Eli Lilly and Company, a leading global pharmaceutical company. Her role involves research and development of innovative drug solutions aimed at improving patient care and outcomes. Her six patents reflect her dedication to innovation and her impact on the pharmaceutical industry.

Collaborations

Throughout her career, Nuria has collaborated with esteemed colleagues, including Concepcion Pedregal-Tercero and Charles Howard Mitch. These collaborations highlight the importance of teamwork and the exchange of ideas in driving innovation and achieving successful research outcomes.

Conclusion

Nuria Diaz Buezo’s contributions to pharmaceutical innovations are commendable. With her impressive patent portfolio and ongoing collaborative efforts, she continues to make meaningful advancements in the treatment of critical health conditions. Her work not only reflects her expertise as an inventor but also underscores the essential role of innovation in the healthcare sector.

Profile summary based on public USPTO records.